


## Foscarnet trisodium hexahydrate

<b>Cat. No.:</b>	HY-W013256		
<b>CAS No.:</b>	34156-56-4		
<b>Molecular Formula:</b>	CH <sub>12</sub> Na <sub>3</sub> O <sub>11</sub> P		
<b>Molecular Weight:</b>	300.04		
<b>Target:</b>	DNA/RNA Synthesis		
<b>Pathway:</b>	Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (166.64 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.3329 mL	16.6644 mL	33.3289 mL
	5 mM	0.6666 mL	3.3329 mL	6.6658 mL
	10 mM	0.3333 mL	1.6664 mL	3.3329 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Foscarnet trisodium hexahydrate (Trisodium phosphonatoformate hexahydrate) is a viral DNA polymerase activity inhibitor, leading to reversible suppression of viral replication. Foscarnet trisodium hexahydrate is an antiherpesvirus agent used in cytomegalovirus retinitis<sup>[1][2][3]</sup>.

#### In Vitro

Foscarnet sodium (Phosphonoformic acid) inhibit the human cytomegalovirus DNA polymerase (UL54) by mimicking the pyrophosphate leaving group of the nucleotide transfer reaction<sup>[1]</sup>.

Foscarnet sodium (Trisodium phosphonoformate) inhibits Influenza A Victoria (IC<sub>50</sub>=29 μM), Influenza B HK (IC<sub>50</sub>=61 μM), and Avian myeloblastosis virus (IC<sub>50</sub>=5-8 μM), HSV-1, several strains (IC<sub>50</sub>=0.4-3.5 μM)<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- J Med Virol. 2022 Nov 27.

- 
- Viruses. 2022 Sep 15;14(9):2049.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Zahn KE, Doublé S, et al. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. J Biol Chem. 2011 Jul 15;286(28):25246-55.
- [2]. Oberg B, et al. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol Ther. 1982;19(3):387-415.
- [3]. Hakki M, et al. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. Curr Hematol Malig Rep. 2020 Jan 24.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA